Trolamine Salicylate
CAS 2174-16-5
Trolamine Salicylate (CAS 2174-16-5) is a pharmaceutical compound with 0 bioactivity targets and 81 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| TEA-SALICYLATE | 38866 | SU | MTHSPL |
| TROLAMINE SALICYLATE | 38866 | SU | MTHSPL |
| Trolamine Salicylate | 38866 | SU | MTHSPL |
| trolamine salicylate | 38866 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Trolamine Salicylate used for in pharmaceutical contexts?
Trolamine Salicylate (CAS 2174-16-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Trolamine Salicylate?
Trolamine Salicylate has 81 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Brain fog, Dizziness, Dyspnoea, Hypotension, Incorrect route of product administration. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Trolamine Salicylate also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for TEA-Salicylate with EU status "restricted".
What clinical phase is Trolamine Salicylate in?
No phase 1-4 clinical development badge is rendered for Trolamine Salicylate because the matched compound identifier rows do not contain a max-phase value.